Medicus Pharma Receives FDA Feedback for Phase 2 Teverelix Clinical Trial

Medicus Pharma (NASDAQ: MDCX) has received written feedback from the U.S. Food and Drug Administration (FDA) along with Central Institutional Review Board (IRB) approval, with modifications, for its optimized Phase 2 clinical trial evaluating Teverelix DP in men following a first episode of acute urinary retention (AUR). The study is designed to assess the therapy’s effects on prostate volume and urinary function.

The randomized, double-blind, placebo-controlled, multicenter study will enroll approximately 126 patients across the United States and Europe under the company’s existing Investigational New Drug (IND) application. The regulatory feedback represents another important milestone as Medicus Pharma advances the clinical development of Teverelix for urological conditions.

#MedicusPharma
#MDCX
#Teverelix
#ClinicalTrials
#FDA
#Biotechnology
#HealthcareInnovation
#Urology
#ProstateHealth
#DrugDevelopment
#LifeSciences
#MedicalResearch
#NASDAQ
#JaneKing
#NewsOut